Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980948 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
A Phase 1 study of Chronic Neuropathic Pain, sponsored by Sangamo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 10
- Study locations
NCT06980948 is a Phase 1 study of Chronic Neuropathic Pain that is actively recruiting participants, run by Sangamo Therapeutics. The registered enrollment target is 27 participants, below the 80-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (66% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT06980948, a Phase 1 study of Chronic Neuropathic Pain, is actively recruiting participants, sponsored by Sangamo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 10
- Study locations
Study Summary
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Conditions Studied
Interventions
- PROCEDURE Sham (No Treatment)
- GENETIC ST-503
Study Locations (10)
Arizona
- HonorHealth - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
New York
- Columbia University - New York
North Carolina
- University of North Carolina Medical Center - Chapel Hill
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-10 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06980948
The ClinicalTrials.gov registry entry for NCT06980948 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (66% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Sham (No Treatment) is the first listed.
NCT06980948 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Arkansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT06980948 about?
NCT06980948 is a clinical study titled "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)". This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due ...
What is the current status of trial NCT06980948?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-10. Estimated completion is 2028-07.
What conditions does trial NCT06980948 study?
This clinical trial studies the following conditions: Chronic Neuropathic Pain.
What interventions are being tested in trial NCT06980948?
The interventions under investigation include: Sham (No Treatment) (PROCEDURE), ST-503 (GENETIC).
Who is sponsoring clinical trial NCT06980948?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980948 being conducted?
This trial has 10 study locations across Arizona, Arkansas, Maryland, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.